ACADIA Pharmaceuticals Inc. vs Expedia Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Expedia Group Inc trades at $321 (market cap $38.53B). The key difference: Expedia Group Inc is far larger — about 7.6× ACADIA Pharmaceuticals Inc.'s market cap, and Expedia Group Inc pays a 0.6% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | EXPE | |
|---|---|---|
Market Cap | $5.07B | $38.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $321.07 |
52-Week Low | $20.06 | $188.51 |
Enterprise Value | $4.19B | $37.09B |
Dividend Yield | — | 0.6% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →